Peptides for Immune Support: Thymosin Alpha-1 and LL-37

Immune-modulating peptides occupy a narrower band of the catalogue than longevity or healing compounds. The cluster centres on one compound with substantial clinical history (thymosin alpha-1), one research compound with strong mechanistic interest (LL-37 and the host-defence peptide family), and a wider research field that has not yet translated to the clinic. This pillar maps the credible cases and is explicit about where the rest of the immune-peptide marketing claims sit.

Key takeaways#

• Thymosin alpha-1 (TA-1) is the anchor compound. It is sold as Zadaxin for chronic hepatitis B and the FDA confirms approval in Italy; the widely quoted "35 countries" comes from the manufacturer's annual report, which the FDA says it cannot verify. Its human evidence base is the largest in the immune-peptide catalogue, though its best-designed trials have not shown clear efficacy.
• In the US, TA-1 is not FDA-approved and cannot be compounded: an FDA advisory committee voted 4 to 17 against adding it to the 503A bulks list in December 2024.
• The COVID-19 pandemic produced a measurable acceleration in TA-1 research. The evidence is almost entirely observational and mixed: an early Wuhan cohort reported lower mortality, while larger later cohorts did not confirm a mortality benefit.
• LL-37 and related host-defence peptides are an active research area, but human dosing data is essentially absent. The cluster includes them as a research signal, not a protocol option.
• Compounds marketed as "immune-boosting peptides" outside this narrow group rarely have the evidence to back the claim. The credible space is smaller than the marketing implies.
• Klarovel does not sell, source, or fulfil peptides. The catalogue here is the protocol and education layer.

How the immune-peptide field actually looks#

A pillar in this category has to navigate two failure modes at once. The first is dismissal: a reader who has seen the "immune-boost" marketing on social media is right to be skeptical, because most of what is sold under that label is not supported by published research. The second is missing the genuine signal: thymosin alpha-1 has decades of human use, an approved product in Italy and a presence in Asian markets, and a publication record that no other peptide in this cluster has.

The honest framing for the field: a single compound carries most of the credible weight, and the rest of the cluster is interesting research without a protocol-ready data set. That asymmetry is unusual. In the GLP-1 cluster, multiple compounds have FDA approval. In the healing cluster, multiple compounds have decades of preclinical research and practitioner use. In immune support, one compound holds the clinical line and the rest of the field is at an earlier stage.

Immune-peptide cluster map

Thymosin alpha-1: the anchor compound#

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from calf thymus extract in the 1970s and subsequently produced synthetically. It is marketed under the brand name Zadaxin in jurisdictions where it is approved. The mechanism cluster involves dendritic cell maturation, T-cell differentiation, and modulation of cytokine production in a direction that broadly favours Th1 (cell-mediated) immunity.

The regulatory footprint matters here. Zadaxin's registration indication is chronic hepatitis B, as monotherapy or with interferon. The manufacturer's 2014 annual report claims approval across Asia-Pacific, Latin America, Eastern Europe and the Middle East, including uses as a chemotherapy adjunct, but the FDA states it cannot independently verify those approvals and confirms only that TA-1 is approved in Europe in Italy (FDA briefing document). The FDA has not approved it for any indication, and in December 2024 its compounding advisory committee voted 4 to 17 against adding it to the 503A bulks list, so it cannot be compounded in the US either (FDA minutes). The Norwegian Direktoratet for medisinske produkter (DMP) does not have it on its approved list either.

The published trial data: multiple randomized controlled trials in chronic hepatitis B, with effect sizes that vary across studies; when the FDA reviewed them in 2024 it concluded the evidence was insufficient to determine effectiveness, and the one double-blind placebo-controlled monotherapy trial it identified was null. In sepsis, the largest trial (TESTS, 1,106 patients, 2025) found no 28-day mortality benefit (PubMed). The oncological adjunct case has weaker individual studies but a broader case-series base. The COVID-19 literature produced a mixed, mostly observational signal. A frequently-cited retrospective study of 76 severe patients in Wuhan reported that TA-1 was associated with lower mortality (11.1% vs 30.0%). Later, larger cohorts did not confirm a mortality benefit, and a 2022 meta-analysis in International Immunopharmacology pooled this largely observational record.

For the protocol reader, the thymosin alpha-1 complete guide covers the mechanism, the indication-by-indication evidence base, and the protocol logic in detail. The credible use cases sit inside specific clinical contexts (chronic viral infection, immunosuppression, sepsis recovery), not in a general "wellness" framing.

LL-37 and the host-defence peptide family#

LL-37 is a cathelicidin, a class of antimicrobial peptides that the body produces endogenously as part of innate immune defence. The mechanism is direct: LL-37 disrupts bacterial membranes, modulates inflammatory cytokine release, and influences dendritic cell function. The research literature is substantial; preclinical evidence supports activity against bacteria, viruses, and certain fungi.

What is missing is human dosing data for exogenous LL-37 as a therapeutic. The endogenous version is constitutively produced and is part of normal physiology. The injectable-LL-37 protocol space has been explored in early-phase trials in specific indications (chronic wounds, diabetic foot ulcers), with signals that have not advanced to FDA or EMA approval. In the US, the FDA removed cathelicidin LL-37 from its Category 2 compounding safety list in April 2026 and has scheduled it for its Pharmacy Compounding Advisory Committee before the end of February 2027; no vote has been taken, so it cannot currently be compounded.

The reason LL-37 belongs in this pillar map: it represents the research direction the immune-peptide field is moving in. Host-defence peptides are likely to be the next category that produces clinical-grade evidence. Studies have shown the protocol-ready dosing recommendations are not yet available in 2026, and preliminary evidence suggests the field will take several more trial cycles to translate.

What the rest of the "immune support" peptide market is#

Outside thymosin alpha-1, the immune-peptide marketing landscape is mostly compounds whose immune claims are mechanistically plausible but clinically unsubstantiated. Thymulin (a different thymic peptide) has limited human research. Beta-defensins are research compounds. Various proprietary blends and "peptide stacks" advertised for immune support do not typically have published efficacy data for the immune endpoint they claim.

The honest editorial framing: if a compound is marketed as immune-supporting and is not thymosin alpha-1, the evidence to back the claim is thinner than the marketing implies. The are peptides safe pillar covers the broader sourcing-quality and contraindication picture that applies to anything in the unregulated peptide market.

When immune-modulating peptides actually fit a protocol#

The immune-modulator class is a clinical-context tool, not a healthy-person enhancement. The contexts where TA-1 is most credibly used in published research:

The first is during or after a serious infection where the immune system is depleted or dysregulated. Sepsis recovery and severe viral illness are the strongest cases. The second is as an adjunct during immunosuppressive cancer treatment, where the mechanism (T-cell support) addresses a specific deficit. The third is in chronic viral infection where the host's adaptive response is failing to clear the pathogen, with chronic hepatitis B being the canonical example.

Outside those contexts, the case for routine TA-1 use in otherwise healthy adults is weak. The protocol layer at Klarovel does not recommend immune-modulating peptides as a default for users without one of the clinical contexts above. The US compounding bar (the December 2024 4-to-17 vote), the unapproved status in Norway and the US, and the absence of healthy-population trial data combine to make this a clinician-supervised category, not a consumer-protocol category.

Where this cluster goes next#

The immune-peptide cluster will widen as the LL-37 and host-defence peptide research catches up to the thymosin alpha-1 evidence base. For now, the credible centre of gravity is one compound with strong evidence in specific clinical contexts and a broader research field that is interesting but not yet protocol-ready.

The honest framing matters in this category more than most. "Peptides for immune support" has been a marketing slogan for several years. The reality is that the credible space is narrow, the clinical contexts are specific, and the rest of the field is at an earlier stage than the marketing implies.

For protocol decisions that engage with this cluster, the Klarovel questionnaire is the starting point. The protocol layer matches profile and context to evidence-quality, not to category-marketing.

• KPV vs Thymosin Alpha-1: Which Wins for Gut and Immune?: KPV calms inflammation in the gut and skin.
• Thymosin Alpha-1: Complete Guide to the Immune Peptide: Thymosin alpha-1 explained: mechanism, the hepatitis B reference dose, sepsis and COVID-19 trial data, safety profile, and what the research actually shows.